What baseline and follow-up laboratory tests are recommended when starting mirtazapine (Remeron)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Laboratory Monitoring for Mirtazapine (Remeron)

No routine baseline or follow-up laboratory testing is required when starting mirtazapine in healthy adults. Unlike mood stabilizers such as lithium or valproate that require regular lab monitoring, mirtazapine does not have established laboratory monitoring requirements in clinical guidelines or FDA labeling 1.

Baseline Assessment

Obtain labs only if clinically indicated based on patient-specific risk factors:

  • Complete blood count (CBC) - Consider in patients with history of blood dyscrasias or concurrent medications that affect bone marrow
  • Liver function tests (ALT, AST) - Consider in patients with known liver disease, heavy alcohol use, or taking hepatotoxic medications
  • Lipid panel and fasting glucose - Consider in patients with metabolic syndrome risk factors, though mirtazapine itself can cause weight gain and metabolic changes 2
  • Pregnancy test - In women of childbearing potential 3

The FDA label for mirtazapine does not mandate any baseline laboratory testing 1. This contrasts sharply with other psychotropic medications: lithium requires CBC, thyroid function, renal function, and calcium at baseline 3; valproate requires liver function tests, CBC, and pregnancy testing 3.

Follow-Up Monitoring

No routine laboratory monitoring is required during mirtazapine treatment. The primary monitoring should focus on:

  • Weight and BMI - Monitor regularly due to mirtazapine's propensity to cause weight gain and increased appetite 4, 5, 6
  • Clinical assessment - Monthly evaluation for therapeutic response and adverse effects
  • Blood pressure - Periodic checks, though mirtazapine typically does not affect blood pressure 6

Special Circumstances Requiring Labs

Order CBC immediately if:

  • Patient develops fever, sore throat, stomatitis, or other signs of infection
  • Suspected agranulocytosis or severe neutropenia (rare but serious adverse effect) 5, 6, 7

Consider lipid panel and glucose if:

  • Significant weight gain occurs (>10% body weight)
  • Patient develops metabolic syndrome symptoms 2

Important Caveats

The lack of required laboratory monitoring does not mean mirtazapine is without metabolic effects. Research demonstrates that mirtazapine causes shifts in substrate metabolism toward carbohydrate preference and increases insulin/C-peptide release even without weight gain 2. However, these changes do not currently warrant routine laboratory surveillance.

Therapeutic drug monitoring (TDM) of mirtazapine serum levels is generally not recommended for routine clinical practice, as the correlation between blood levels and clinical response is weak 8, 9. The therapeutic reference range of 30-80 ng/mL exists but has limited clinical utility 10, 8.

This minimal monitoring requirement makes mirtazapine particularly practical compared to mood stabilizers requiring extensive laboratory surveillance every 3-6 months 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.